Merus BV (US:MRUS) — Company Overview, News & Financial Data
Merus BV is a biotechnology company developing bispecific and trispecific antibody therapeutics for cancer treatment.
MRUSMerus BV
Company profile
About Merus BV
Merus BV (NASDAQ:MRUS) is a dynamic biotechnology company focused on developing innovative, full-length human bispecific and trispecific antibody therapeutics. With a deep commitment to addressing unmet medical needs, Merus is dedicated to advancing a broad pipeline of therapies aimed at treating various types of cancer. Unique to its approach is the use of its proprietary Biclonics® and Triclonics® technology platforms, designed to produce antibodies that can engage multiple targets simultaneously, offering potential for more effective treatments. The company strives to transform cancer treatment paradigms, working tirelessly toward achieving dramatic improvements in patient outcomes.
Snapshot
Public USOwnership
2003Year founded
240Employees
Utrecht, NetherlandsHead office
Loading Map...
Global footprint
Operations
All Locations
Kingdom of the Netherlands
Products and/or services of Merus BV
- Zenocutuzumab (MCLA-128) targets HER2- and NRG1-fusion cancers, addressing unmet needs in non-small cell lung and pancreatic cancers.
- MCLA-117 is a bispecific antibody aiming to treat acute myeloid leukemia by engaging CLEC12A and CD3.
- MCLA-158 focuses on solid tumors by targeting LGR5 and EGFR, potentially disrupting cancer stem cells.
- Ona-Cel (MCLA-145) acts as a dual PD-L1 and CD137 immunotherapy, designed for advanced solid tumors.
- MCLA-129 combines EGFR and c-MET targeting, aimed at treating solid tumors with enhanced potency.
- MCLA-158 is being explored for its potential in head and neck cancer, leveraging bispecific targeting for tumor selectivity.
Merus BV executive team
- Mr. Gregory D. PerryChief Financial Officer
- Mr. Peter B. Silverman J.D.EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
- Dr. Fabian Zohren M.D., Ph.D.Chief Medical Officer
- Dr. Jan G.J. van de Winkel Ph.D.CEO & Executive Director
- Dr. Hennie HoogenboomCo-Founder and Scientific Advisor
- Mr. Harry ShumanChief Accounting Officer
- Mr. Cornelis Adriaan de Kruif Ph.D.CTO & Executive VP
- Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VP
- Ms. Sherri SpearSenior Vice President of Investor Relations & Strategic Communications
- Ms. Kathleen FarrenDirector of IR & Corporate Communications Officer